SARS-CoV-2 co-detection with other respiratory pathogens-descriptive epidemiological study.

FILMARRAY® Multiplex PCR testing SARS-CoV-2 co-detection respiratory pathogens

Journal

Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124

Informations de publication

Date de publication:
03 Aug 2024
Historique:
received: 17 05 2024
revised: 15 07 2024
accepted: 23 07 2024
medline: 5 8 2024
pubmed: 5 8 2024
entrez: 4 8 2024
Statut: aheadofprint

Résumé

Co-detection of respiratory pathogens with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is poorly understood. This descriptive epidemiological study aimed to determine the effect of the interaction of different respiratory pathogens on clinical variables. We retrospectively reviewed the results of comprehensive multiplex polymerase chain reaction (PCR) testing from November 2020 to March 2023 to estimate respiratory pathogen co-detection rates in Shinjuku, Tokyo. We evaluated the interactions of respiratory pathogens, particularly SARS-CoV-2, between observed and expected co-detection. We estimated the trend of co-detection with SARS-CoV-2 in terms of age and sex and applied a multiple logistic regression model adjusted for age, testing period, and sex to identify influencing factors between co-detection and single detection for each pathogen. Among 57,746 patients who underwent multiplex PCR testing, 10,516 (18.2%) had positive for at least one of the 22 pathogens. Additionally, 881 (1.5%) patients were confirmed to have a co-detection. SARS-CoV-2 exhibited negative interactions with adenovirus, coronavirus, human metapneumovirus, parainfluenza virus, respiratory syncytial virus, and rhino/enterovirus. SARS-CoV-2 co-detection with other pathogens occurred most frequently in patients of the youngest age group (0-4 years). A multiple logistic regression model indicated that younger age was the most influential factor for SARS-CoV-2 co-detection with other respiratory pathogens. The study highlights the prevalence of SARS-CoV-2 co-detection with other respiratory pathogens in younger age groups, necessitating further exploration of the clinical implications and severity of SARS-CoV-2 co-detection.

Sections du résumé

BACKGROUND BACKGROUND
Co-detection of respiratory pathogens with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is poorly understood. This descriptive epidemiological study aimed to determine the effect of the interaction of different respiratory pathogens on clinical variables.
METHODS METHODS
We retrospectively reviewed the results of comprehensive multiplex polymerase chain reaction (PCR) testing from November 2020 to March 2023 to estimate respiratory pathogen co-detection rates in Shinjuku, Tokyo. We evaluated the interactions of respiratory pathogens, particularly SARS-CoV-2, between observed and expected co-detection. We estimated the trend of co-detection with SARS-CoV-2 in terms of age and sex and applied a multiple logistic regression model adjusted for age, testing period, and sex to identify influencing factors between co-detection and single detection for each pathogen.
RESULTS RESULTS
Among 57,746 patients who underwent multiplex PCR testing, 10,516 (18.2%) had positive for at least one of the 22 pathogens. Additionally, 881 (1.5%) patients were confirmed to have a co-detection. SARS-CoV-2 exhibited negative interactions with adenovirus, coronavirus, human metapneumovirus, parainfluenza virus, respiratory syncytial virus, and rhino/enterovirus. SARS-CoV-2 co-detection with other pathogens occurred most frequently in patients of the youngest age group (0-4 years). A multiple logistic regression model indicated that younger age was the most influential factor for SARS-CoV-2 co-detection with other respiratory pathogens.
CONCLUSION CONCLUSIONS
The study highlights the prevalence of SARS-CoV-2 co-detection with other respiratory pathogens in younger age groups, necessitating further exploration of the clinical implications and severity of SARS-CoV-2 co-detection.

Identifiants

pubmed: 39098246
pii: S2212-5345(24)00117-5
doi: 10.1016/j.resinv.2024.07.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

884-888

Informations de copyright

Copyright © 2024 The Author. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that this study was performed in the absence of commercial or financial relationships that could be construed as potential conflicts of interest. The authors have no conflicts of interest.

Auteurs

Ken Arimura (K)

Tokyo Women's Medical University, Department of Respiratory Medicine, 8-1, Kawadacho, Shinjuku, Tokyo, 1628666, Japan. Electronic address: arimura.ken@twmu.ac.jp.

Ken Kikuchi (K)

Tokyo Women's Medical University, Department of Infectious Diseases, 8-1, Kawadacho, Shinjuku, Tokyo, 1628666, Japan.

Yasuto Sato (Y)

Shizuoka Graduate University of Public Health, Graduate School of Public Health, 4-27-2, Kita ando, Aoi, Shizuoka, Shizuoka, 4200881, Japan.

Hitomi Miura (H)

Tokyo Women's Medical University Hospital, Central Clinical Laboratory, 8-1, Kawadacho, Shinjuku, Tokyo, 1628666, Japan.

Asako Sato (A)

Tokyo Women's Medical University Hospital, Department of Clinical Laboratory, 8-1, Kawadacho, Shinjuku, Tokyo, 1628666, Japan.

Hideki Katsura (H)

Tokyo Women's Medical University, Department of Respiratory Medicine, 8-1, Kawadacho, Shinjuku, Tokyo, 1628666, Japan.

Mitsuko Kondo (M)

Tokyo Women's Medical University, Department of Respiratory Medicine, 8-1, Kawadacho, Shinjuku, Tokyo, 1628666, Japan.

Michio Itabashi (M)

Tokyo Women's Medical University, Department of Surgery, Division of Inflammatory Bowel Disease Surgery, 8-1, Kawadacho, Shinjuku, Tokyo, 1628666, Japan.

Etsuko Tagaya (E)

Tokyo Women's Medical University, Department of Respiratory Medicine, 8-1, Kawadacho, Shinjuku, Tokyo, 1628666, Japan.

Classifications MeSH